The PERKs of mitochondria protection during stress: insights for PERK modulation in neurodegenerative and metabolic diseases

Liliana M. Almeida,Brígida R. Pinho,Michael R. Duchen,Jorge M. A. Oliveira
DOI: https://doi.org/10.1111/brv.12860
IF: 14.35
2022-04-26
Biological Reviews
Abstract:Protein kinase RNA‐like ER kinase (PERK) is an endoplasmic reticulum (ER) stress sensor that responds to the accumulation of misfolded proteins. Once activated, PERK initiates signalling pathways that halt general protein production, increase the efficiency of ER quality control, and maintain redox homeostasis. PERK activation also protects mitochondrial homeostasis during stress. The location of PERK at the contact sites between the ER and the mitochondria creates a PERK–mitochondria axis that allows PERK to detect stress in both organelles, adapt their functions and prevent apoptosis. During ER stress, PERK activation triggers mitochondrial hyperfusion, preventing premature apoptotic fragmentation of the mitochondria. PERK activation also increases the formation of mitochondrial cristae and the assembly of respiratory supercomplexes, enhancing cellular ATP‐generating capacity. PERK strengthens mitochondrial quality control during stress by promoting the expression of mitochondrial chaperones and proteases and by increasing mitochondrial biogenesis and mitophagy, resulting in renewal of the mitochondrial network. But how does PERK mediate all these changes in mitochondrial homeostasis? In addition to the classic PERK–eukaryotic translation initiation factor 2α (eIF2α)–activating transcription factor 4 (ATF4) pathway, PERK can activate other protective pathways – PERK–O‐linked N‐acetyl‐glucosamine transferase (OGT), PERK–transcription factor EB (TFEB), and PERK–nuclear factor erythroid 2‐related factor 2 (NRF2) – contributing to broader regulation of mitochondrial dynamics, metabolism, and quality control. The pharmacological activation of PERK is protective in models of neurodegenerative and metabolic diseases, such as Huntington's disease, progressive supranuclear palsy and obesity, while the inhibition of PERK was protective in models of Parkinson's and prion diseases and diabetes. In this review, we address the molecular mechanisms by which PERK regulates mitochondrial dynamics, metabolism and quality control, and discuss the therapeutic potential of targeting PERK in neurodegenerative and metabolic diseases.
biology
What problem does this paper attempt to address?